Table of Content

1 Market
1.1 Product Definition
1.2 Inclusion and Exclusion Criteria
1.3 Market Scope
1.3.1 Key Questions Answered
1.4 Research Methodology
1.4.1 Global NK Cell Therapeutics Market: Research Methodology
1.4.2 Primary Data Sources
1.4.3 Secondary Data Sources
1.5 Market Estimation Model
1.6 Criteria for Company Profiling
1.7 Market Overview
1.7.1 Introduction
1.7.2 Evolution of NK Cell Therapeutics
1.7.3 Types of NK Cell Therapeutics
1.7.4 Source of NK Cell Therapeutics
1.7.5 Mechanism of Action: NK Cell Therapies
1.7.5.1 Application of NK Cell Therapeutics in Disease Areas
1.7.5.1.1 Cancer
1.7.5.1.2 Acute Infectious Disease
1.7.6 Role of NK Cell Therapeutics in COVID-19
1.7.7 Comparison between Car T-Cell Therapy and NK Cell Therapy
1.7.8 Advantages and Limitations of NK Cell Therapeutics
1.7.9 Current Market Size and Growth Potential, $Million, 2022-2032
1.7.10 COVID-19 Impact on Global NK Cell Therapeutics Market
1.7.10.1 Overview
1.7.10.2 Research and Clinical Development Interruption in Global NK Cell Therapeutics Market

2 Pipeline Analysis
2.1 Global NK Cell Therapeutics Market Pipeline Analysis
2.2 Probable Potential First Entrants to Global NK Cell Therapeutics Market
2.2.1 Overview
2.2.2 AFM13
2.2.2.1 Product Profile
2.2.2.2 AFM13 Phase II Study Design
2.2.3 MG4101
2.2.3.1 Product Profile
2.2.3.2 MG4101 Phase II Study Design
2.2.4 GTA002 (oNKord)
2.2.4.1 Product Profile
2.2.4.2 GTA002 (oNKord) Phase II Study Design
2.2.5 TAK-007
2.2.5.1 Product Profile
2.2.5.2 TAK-007 Phase II Study Design

3 Industry Analysis
3.1 Overview
3.2 Legal Requirements and Framework in the U.S.
3.2.1 Clinical Trial Authorization
3.2.2 Marketing Authorization
3.2.3 U.S. Food and Drug Administration Guidelines for Biologics License Application (BLA)
3.2.4 Post-Authorization Regulations
3.3 Legal Requirements and Frameworks in Europe
3.4 Legal Requirements and Framework in Japan
3.5 Legal Requirements and Framework in South Korea
3.6 Reimbursement Scenario in the U.S.
3.7 Reimbursement Scenario in Europe

4 Market Dynamics
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Rising Number of Clinical Trials
4.3.2 Increasing Incidence and Prevalence of Cancer
4.4 Market Restraints
4.4.1 Lack of Specificity and Poor In Vivo Survival of the NK Cells
4.4.2 High Cost of Immunotherapy Treatment Associated with Cancer
4.5 Market Opportunities
4.5.1 Increasing Funding and Investment
4.5.2 Rising Number of Partnerships and Collaborations

5 Market Analysis
5.1 Global NK Cell Therapeutics Market (by Therapy Type), $Million, 2024-2032
5.1.1 Overview
5.1.2 NK Cell Therapy (Unmodified)
5.1.3 CAR-NK Cell Therapy (Modified)
5.1.4 NK Cell Engagers
5.2 Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024-2032
5.2.1 Overview
5.2.2 AFM13
5.2.3 MG4101
5.2.4 GTA002 (oNKord)
5.2.5 TAK-007
5.3 Global NK Cell Therapeutics Market (by Indication), $Million, 2024-2032
5.3.1 Overview
5.3.2 Acute Myeloid Leukemia
5.3.3 Hepatocellular Carcinoma
5.3.4 Peripheral T-Cell Lymphoma
5.3.5 Relapsed or Refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
5.4 Global NK Cell Therapeutics Market (by Country), $Million, 2024-2032
5.4.1 Overview
5.4.2 U.S.
5.4.3 U.K.
5.4.4 Germany
5.4.5 France
5.4.6 Italy
5.4.7 Spain
5.4.8 Japan
5.4.9 South Korea

6 Market - Competitive Benchmarking & Company Profiles
6.1 Competitive Landscape
6.1.1 Clinical Developments
6.1.2 Regulatory and Legal Activities
6.1.3 Partnerships and Alliances
6.1.4 Funding Activities
6.1.4.1 Institutional Fundings
6.1.5 Business Expansions
6.2 Company Profiles
6.2.1 Overview
6.2.2 Affimed N.V.
6.2.2.1 Company Overview
6.2.2.2 Role of Affimed N.V. in the Global NK Cell Therapeutics Market
6.2.2.3 Key Competitors of the Company
6.2.2.4 Financials
6.2.2.5 Key Insight about the Financial Health of the Company
6.2.2.6 Business Strategies
6.2.2.7 Analyst Perspective
6.2.3 Century Therapeutics, Inc.
6.2.3.1 Company Overview
6.2.3.2 Role of Century Therapeutics, Inc. in the Global NK Cell Therapeutics Market
6.2.3.3 Key Competitors of the Company
6.2.3.4 Financials
6.2.3.5 Key Insight about the Financial Health of the Company
6.2.3.6 Business Strategies
6.2.3.7 Analyst Perspective
6.2.4 Celularity Inc.
6.2.4.1 Company Overview
6.2.4.2 Role of Celularity Inc. in the Global NK Cell Therapeutics Market
6.2.4.3 Key Competitors of the Company
6.2.4.4 Financials
6.2.4.5 Key Insight about the Financial Health of the Company
6.2.4.6 Business Strategies
6.2.4.7 Analyst Perspective
6.2.5 Cytovac A/S
6.2.5.1 Company Overview
6.2.5.2 Role of Cytovac A/S in Global NK Cell Therapeutics Market
6.2.5.3 Key Competitors of the Company
6.2.5.4 Analyst Perspective
6.2.6 Dragonfly Therapeutics, Inc.
6.2.6.1 Company Overview
6.2.6.2 Role of Dragonfly Therapeutics, Inc. in the Global NK Cell Therapeutics Market
6.2.6.3 Key Competitors of the Company
6.2.6.4 Business Strategies
6.2.6.5 Analyst Perspective
6.2.7 Fate Therapeutics, Inc.
6.2.7.1 Company Overview
6.2.7.2 Role of Fate Therapeutics, Inc. in the Global NK Cell Therapeutics Market
6.2.7.3 Key Competitors of the Company
6.2.7.4 Financials
6.2.7.5 Key Insight about the Financial Health of the Company
6.2.7.6 Business Strategies
6.2.7.7 Analyst Perspective
6.2.8 Gamida Cell Ltd.
6.2.8.1 Company Overview
6.2.8.2 Role of Gamida Cell Ltd. in the Global NK Cell Therapeutics Market
6.2.8.3 Key Competitors of the Company
6.2.8.4 Financials
6.2.8.5 Key Insight about the Financial Health of the Company
6.2.8.6 Analyst Perspective
6.2.9 GC Cell (GC Biopharma corp.)
6.2.9.1 Company Overview
6.2.9.2 Role of GC Cell (GC Biopharma corp.) in Global NK Cell Therapeutics Market
6.2.9.3 Key Competitors of the Company
6.2.9.4 Financials
6.2.9.5 Business Strategies
6.2.9.6 Analyst Perspective
6.2.10 Glycostem Therapeutics B.V.
6.2.10.1 Company Overview
6.2.10.2 Role of Glycostem Therapeutics B.V. in the Global NK Cell Therapeutics Market
6.2.10.3 Key Competitors of the Company
6.2.10.4 Business Strategies
6.2.10.5 Analyst Perspective
6.2.11 ImmunityBio, Inc.
6.2.11.1 Company Overview
6.2.11.2 Role of ImmunityBio, Inc. in the Global NK Cell Therapeutics Market
6.2.11.3 Key Competitors of the Company
6.2.11.4 Financials
6.2.11.5 Key Insight about the Financial Health of the Company
6.2.11.6 Business Strategies
6.2.11.7 Analyst Perspective
6.2.12 Innate Pharma SA
6.2.12.1 Company Overview
6.2.12.2 Role of Innate Pharma SA in the Global NK Cell Therapeutics Market
6.2.12.3 Key Competitors of the Company
6.2.12.4 Financials
6.2.12.5 Key Insight about the Financial Health of the Company
6.2.12.6 Business Strategies
6.2.12.7 Analyst Perspective
6.2.13 Nkarta, Inc.
6.2.13.1 Company Overview
6.2.13.2 Role of Nkarta, Inc. in the Global NK Cell Therapeutics Market
6.2.13.3 Key Competitors of the Company
6.2.13.4 Financials
6.2.13.5 Key Insight about the Financial Health of the Company
6.2.13.6 Business Strategies
6.2.13.7 Analyst Perspective
6.2.14 Sanofi S.A.
6.2.14.1 Company Overview
6.2.14.2 Role of Sanofi S.A. in the Global NK Cell Therapeutics Market
6.2.14.3 Key Competitors of the Company
6.2.14.4 Financials
6.2.14.5 Key Insight about the Financial Health of the Company
6.2.14.6 Business Strategies
6.2.14.7 Analyst Perspective
6.2.15 Takeda Pharmaceutical Company Limited
6.2.15.1 Company Overview
6.2.15.2 Role of Takeda Pharmaceutical Company Limited in the Global NK Cell Therapeutics Market
6.2.15.3 Key Competitors of the Company
6.2.15.4 Financials
6.2.15.5 Key Insight about the Financial Health of the Company
6.2.15.6 Analyst Perspective
6.2.16 VaxCell Biotherapeutics Co., Ltd.
6.2.16.1 Company Overview
6.2.16.2 Role of VaxCell Biotherapeutics Co., Ltd. in the Global NK Cell Therapeutics Market
6.2.16.3 Key Competitors of the Company
6.2.16.4 Analyst Perspective
6.3 Emerging Companies
6.3.1 Overview
6.3.2 Acepodia Inc.
6.3.2.1 Company Overview
6.3.2.2 Role of Acepodia Inc. in the Global NK Cell Therapeutics Market
6.3.2.3 Key Competitors of the Company
6.3.2.4 Analyst Perspective
6.3.3 iCell Gene Therapeutics
6.3.3.1 Company Overview
6.3.3.2 Role of iCell Gene Therapeutics in the Global NK Cell Therapeutics Market
6.3.3.3 Key Competitors of the Company
6.3.3.4 Analyst Perspective
6.3.4 Senti Biosciences
6.3.4.1 Company Overview
6.3.4.2 Role of Senti Biosciences in Global NK Cell Therapeutics Market
6.3.4.3 Key Competitors of the Company
6.3.4.4 Analyst Perspective
6.3.5 Shoreline Biosciences
6.3.5.1 Company Overview
6.3.5.2 Role of Shoreline Biosciences in the Global NK Cell Therapeutics Market
6.3.5.3 Key Competitors of the Company
6.3.5.4 Analyst Perspective
List of Figures
Figure 1: Immunotherapies Approved by the U.S. Food and Drug Administration (FDA), 2011-2022
Figure 2: NK Cell Therapeutics Clinical Trials (by Phase), 2022
Figure 3: NK Cell Therapeutics Clinical Trials (by Indication), 2022
Figure 4: Global NK Cell Therapeutics Market Growth Revenue, $Million, 2024-2032
Figure 5: Global NK Cell Therapeutics Market (by NK Cell Therapeutics Type), $Million, 2024, 2025, 2026, and 2032
Figure 6: Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024, 2025, 2026, and 2032
Figure 7: Global NK Cell Therapeutics Market (by Indication), $Million, 2024, 2025, 2026, and 2032
Figure 8: Global NK Cell Therapeutics Market (by Region), $Million, 2024-2032
Figure 9: Global NK Cell Therapeutics Market Segmentation
Figure 10: Global NK Cell Therapeutics Market Methodology
Figure 11: Primary Research Methodology
Figure 12: Epidemiology-Based Approach
Figure 13: Types of Immunotherapies
Figure 14: Types of NK Cells
Figure 15: Academic NK Clinical Milestones
Figure 16: Types of NK Cell Therapeutics
Figure 17: NK Cell Interacts with Healthy Cell
Figure 18: NK Cell Interacts with Target Cell
Figure 19: Applications of NK Cell Therapeutics in Disease Areas
Figure 20: Global NK Cell Therapeutics Market Growth Revenue, $Million, 2024-2032
Figure 21: Areas of Disruption in Clinical Development
Figure 22: NK Cell Therapeutics Clinical Trials (by Phase), 2022
Figure 23: NK Cell Therapeutics Clinical Trials (by Indication), 2022
Figure 24: AFM13 Phase II Clinical Design for Peripheral T-Cell Lymphoma
Figure 25: MG4101 Phase II Clinical Design for Hepatocellular Carcinoma, Treatment Group and Control Group
Figure 26: MG4101 Phase II Clinical Design for Hepatocellular Carcinoma
Figure 27: GTA002 (oNKord) Phase II WiNK Trial Stages for Acute Myeloid Leukemia
Figure 28: GTA002 (oNKord) Phase II Clinical Design for Acute Myeloid Leukemia
Figure 29: TAK-007 Phase II Trial Stages for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
Figure 30: TAK-007 Phase II Clinical Design for Relapsed or Refractory (r/r) B-Cell Non-Hodgkin’s Lymphoma (NHL)
Figure 31: Clinical Trial Authorization for NK Cell Therapeutics
Figure 32: Process for Obtaining Marketing Authorization
Figure 33: Procedures Offered by the Food and Drug Administration (FDA) for Drugs Intended to Treat Serious Health Conditions
Figure 34: U.S. Food and Drug Administration Review Timeline
Figure 35: EMA Review Timeline
Figure 36: South Korea Approval Process from Development to Authorization
Figure 37: Reimbursement Scenarios in the U.S. for CAR T-Cell Therapy (Initial and Current Approach)
Figure 38: Current Reimbursement Scenario in Europe
Figure 39: Impact Analysis of Market Drivers
Figure 40: Number of Clinical Trials for NK Cell Therapies (by Year)
Figure 41: Number of Clinical Trials for NK Cell Therapies (by Major Players)
Figure 42: Global Cancer Incidence, 2017-2018
Figure 43: Cancer Incidence (by Region), 2017-2018
Figure 44: Global NK Cell Therapeutics Market (by Therapy Type)
Figure 45: Global NK Cell Therapeutics Market (by Therapy Type), $Million, 2024, 2025, 2026, and 2032
Figure 46: NK Cell Therapy (Unmodified) Market, $Million, 2024-2032
Figure 47: CAR-NK Cell Therapy (Modified) Market, $Million, 2025-2032
Figure 48: NK Cell Engagers Market, $Million, 2026-2032
Figure 49: Global NK Cell Therapeutics Market (by Pipeline Product), $Million, 2024, 2025, 2026, and 2032
Figure 50: Global Revenue for AFM13, $Million, 2026-2032
Figure 51: Global Revenue for MG4101, $Million, 2026-2032
Figure 52: Global Revenue for GTA002 (oNKordA), $Million, 2024-2032
Figure 53: Global Revenue for TAK-007, $Million, 2025-2032
Figure 54: Global NK Cell Therapeutics Market (by Indication), $Million, 2024, 2025, 2026, and 2032
Figure 55: Global NK Cell Therapeutics Market (by Acute Myeloid Leukemia), $Million, 2024-2032
Figure 56: Global NK Cell Therapeutics Market (by Hepatocellular Carcinoma), $Million, 2026-2032
Figure 57: Global NK Cell Therapeutics Market (by Peripheral T-Cell Lymphoma), $Million, 2026-2032
Figure 58: Global NK Cell Therapeutics Market (by Relapsed or Refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)), $Million, 2026-2032
Figure 59: Global NK Cell Therapeutics Market (by Region)
Figure 60: Global NK Cell Therapeutics Market (by Region), $Million, 2024-2032
Figure 61: Global NK Cell Therapeutics Market (by Country), $Million, 2024-2032
Figure 62: U.S. NK Cell Therapeutics Market, $Million, 2024-2032
Figure 63: U.K. NK Cell Therapeutics Market, $Million, 2024-2032
Figure 64: Germany NK Cell Therapeutics Market, $Million, 2024-2032
Figure 65: France NK Cell Therapeutics Market, $Million, 2024-2032
Figure 66: Italy NK Cell Therapeutics Market, $Million, 2024-2032
Figure 67: Spain NK Cell Therapeutics Market, $Million, 2024-2032
Figure 68: Japan NK Cell Therapeutics Market, $Million, 2024-2032
Figure 69: South Korea NK Cell Therapeutics Market, $Million, 2024-2032
Figure 70: Share of Key Developments and Strategies, January 2019-April 2022
Figure 71: Share of Regulatory and Legal Activities (by Company), January 2019-April 2022
Figure 72: Share of Partnerships and Alliances (by Company), January 2019-April 2022
Figure 73: Share of Funding Activities (by Company), January 2019-April 2022
Figure 74: Share of Business Expansions (by Company), January 2019-April 2022
Figure 75: Affimed N.V.: Preclinical and Clinical Assets
Figure 76: Affimed N.V.: Overall Financials, $Million, 2019-2021
Figure 77: Affimed N.V.: Revenue (by Region), $Million, 2019-2021
Figure 78: Affimed N.V.: R&D Expenditure, $Million, 2019-2021
Figure 79: Affimed N.V: R&D Expenditure (by Product), $Million, 2019-2021
Figure 80: Century Therapeutics, Inc.: Preclinical and Clinical Assets
Figure 81: Century Therapeutics, Inc.: Overall Financials, $Million, 2020-2021
Figure 82: Century Therapeutics, Inc.: R&D Expenditure, $Million, 2020-2021
Figure 83: Celularity Inc.: Preclinical and Clinical Assets
Figure 84: Celularity Inc. Overall Financials, $Million, 2020-2021
Figure 85: Celularity Inc.: Revenue (by Segment), $Million, 2020-2021
Figure 86: Celularity Inc.: R&D Expenditure, $Million, 2020-2021
Figure 87: Cytovac A/S: Preclinical and Clinical Assets
Figure 88: Dragonfly Therapeutics, Inc.: Preclinical and Clinical Assets
Figure 89: Fate Therapeutics, Inc.: Preclinical and Clinical Assets
Figure 90: Fate Therapeutics, Inc. Overall Financials, $Million, 2019-2021
Figure 91: Fate Therapeutics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 92: Gamida Cell Ltd.: Preclinical and Clinical Assets
Figure 93: Gamida Cell Ltd. Overall Financials, $Million, 2019-2021
Figure 94: Gamida Cell Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 95: GC Cell (GC Biopharma corp.) Preclinical and Clinical Assets
Figure 96: GC Cell (GC Biopharma corp.) Overall Financials, $Million, 2019-2021
Figure 97: Glycostem Therapeutics B.V.: Preclinical and Clinical Assets
Figure 98: ImmunityBio, Inc.: Preclinical and Clinical Assets
Figure 99: ImmunityBio, Inc.: Overall Financials, $Million, 2019-2021
Figure 100: ImmunityBio, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 101: ImmunityBio, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 102: Innate Pharma SA: Preclinical and Clinical Assets
Figure 103: Innate Pharma SA: Overall Financials, $Million, 2019-2021
Figure 104: Innate Pharma SA: R&D Expenditure, $Million, 2019-2021
Figure 105: Nkarta, Inc.: Preclinical and Clinical Assets
Figure 106: Nkarta, Inc.: Overall Financials, $Million, 2019-2021
Figure 107: Nkarta, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 108: Sanofi S.A.: Preclinical and Clinical Assets
Figure 109: Sanofi S.A.: Overall Financials, $Million, 2019-2021
Figure 110: Sanofi S.A.: Revenue (by Segment), $Million, 2019-2021
Figure 111: Sanofi S.A.: Revenue (by Region), $Million, 2019-2021
Figure 112: Sanofi S.A.: R&D Expenditure, $Million, 2019-2021
Figure 113: Takeda Pharmaceutical Company Limited: Preclinical and Clinical Assets
Figure 114: Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2019-2021
Figure 115: Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2019-2021
Figure 116: Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2019-2021
Figure 117: VaxCell Biotherapeutics Co., Ltd.: Preclinical and Clinical Assets
Figure 118: Acepodia Inc.: Preclinical and Clinical Assets
Figure 119: iCell Gene Therapeutics: Preclinical and Clinical Assets
Figure 120: Senti Biosciences: Preclinical and Clinical Assets
Figure 121: Shoreline Biosciences: Preclinical and Clinical Assets
List of Tables
Table 1: CAR T-Cell Therapy vs. NK Cell Therapy
Table 2: Advantages and Limitations of NK Cell Therapeutics
Table 3: Emerging NK Cell Therapeutics Pipeline
Table 4: Probable Potential First Entrants to Global NK Cell Therapeutics Market
Table 5: Reimbursement Scenario of CAR T-Cell Therapies in EU5 Countries
Table 6: Approximate Cost of the Different Types of Immunotherapies
Table 7: Funding and Investment Activities of the Companies
Table 8: Partnerships and Collaborations of the Companies
Table 9: NK Cell Therapy (Unmodified) Pipeline Products
Table 10: CAR-NK Cell Therapy (Modified) Pipeline Products
Table 11: NK Cell Engagers Pipeline Products
Table 12: NK Cell Therapeutics (Pipeline Products) for Acute Myeloid Leukemia
Table 13: NK Cell Therapeutics (Pipeline Products) for Hepatocellular Carcinoma
Table 14: NK Cell Therapeutics (Pipeline Products) for T-Cell Malignancies and Peripheral T-Cell Lymphoma
Table 15: NK Cell Therapeutics (Pipeline Products) for B-Cell Malignancies
Table 16: List of Key Competitors of Affimed N.V.
Table 17: List of Key Competitors of Century Therapeutics, Inc.
Table 18: List of Key Competitors of Celularity Inc.
Table 19: List of Key Competitors of Cytovac A/S
Table 20: List of Key Competitors of Dragonfly Therapeutics, Inc.
Table 21: List of Key Competitors of Fate Therapeutics, Inc.
Table 22: List of Key Competitors of Gamida Cell Ltd.
Table 23: List of Key Competitors of GC Cell (GC Biopharma corp.)
Table 24: List of Key Competitors of Glycostem Therapeutics B.V.
Table 25: List of Key Competitors of ImmunityBio, Inc.
Table 26: List of Key Competitors of Innate Pharma SA
Table 27: List of Key Competitors of Nkarta, Inc.
Table 28: List of Key Competitors of Sanofi S.A.
Table 29: List of Key Competitors of Takeda Pharmaceutical Company Limited
Table 30: List of Key Competitors of VaxCell Biotherapeutics Co., Ltd.
Table 31: List of Key Competitors of Acepodia Inc.
Table 32: List of Key Competitors of iCell Gene Therapeutics
Table 33: List of Key Competitors of Senti Biosciences
Table 34: List of Key Competitors of Shoreline Biosciences